PMID- 30188915
OWN - NLM
STAT- MEDLINE
DCOM- 20190226
LR  - 20190226
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 13
IP  - 9
DP  - 2018
TI  - Evaluation of various kinetic parameters of CA-125 in patients with
      advanced-stage ovarian cancer undergoing neoadjuvant chemotherapy.
PG  - e0203366
LID - 10.1371/journal.pone.0203366 [doi]
AB  - Various kinetic parameters of serum CA-125 have been reported to have better
      correlation with outcomes for patients treated with neoadjuvant chemotherapy
      (NAC). This study aimed to compare the available kinetic parameters of serum
      CA-125 in an external cohort of advanced-stage ovarian cancer. Using the cancer
      registry databases from the Yonsei Cancer Hospital, we retrospectively reviewed
      210 patients with advanced-stage ovarian cancer, treated with NAC followed by
      interval debulking surgery. We compared area under the receiver-operating
      characteristics curves (AUCs), false negative rate, and negative predictive value
      (NPV) using 10 different models for optimal cytoreduction and platinum
      resistance. In addition, we compared incremental AUC for progression-free
      survival (PFS) and overall survival (OS). No gross residual tumor was observed in
      37.0% and residual tumors <1 cm in 82.2% of patients. No model using CA-125
      kinetic parameters had an AUC higher than >0.6 for predicting optimal
      cytoreduction. After adjusting for age, BMI, disease stage, and histologic
      subtypes, all models had an AUC >0.70 for predicting platinum resistance.
      However, no model had a high enough NPV (highest value = 82.0%) to avoid
      chemotherapy futility. For survival outcomes, no model had an incremental AUC
      >0.70 for predicting either PFS or OS. None of the proposed serum CA-125 kinetic 
      parameters showed high accuracy in predicting optimal cytoreduction, platinum
      resistance, or survival in patients receiving NAC. For advanced-stage ovarian
      cancer treated with NAC, there is a need to discover reliable biomarkers to
      better stratify patient response groups for optimal treatment decision-making.
FAU - Lee, Yong Jae
AU  - Lee YJ
AD  - Department of Obstetrics and Gynecology, Institute of Women's Medical Life
      Science, Yonsei University College of Medicine, Seoul, Korea.
FAU - Lee, In Ha
AU  - Lee IH
AD  - Department of Obstetrics and Gynecology, Institute of Women's Medical Life
      Science, Yonsei University College of Medicine, Seoul, Korea.
FAU - Kim, Yun-Ji
AU  - Kim YJ
AD  - Department of Obstetrics and Gynecology, Institute of Women's Medical Life
      Science, Yonsei University College of Medicine, Seoul, Korea.
FAU - Chung, Young Shin
AU  - Chung YS
AD  - Department of Obstetrics and Gynecology, Institute of Women's Medical Life
      Science, Yonsei University College of Medicine, Seoul, Korea.
FAU - Lee, Jung-Yun
AU  - Lee JY
AUID- ORCID: 0000-0001-7948-1350
AD  - Department of Obstetrics and Gynecology, Institute of Women's Medical Life
      Science, Yonsei University College of Medicine, Seoul, Korea.
FAU - Nam, Eun Ji
AU  - Nam EJ
AD  - Department of Obstetrics and Gynecology, Institute of Women's Medical Life
      Science, Yonsei University College of Medicine, Seoul, Korea.
FAU - Kim, Sunghoon
AU  - Kim S
AD  - Department of Obstetrics and Gynecology, Institute of Women's Medical Life
      Science, Yonsei University College of Medicine, Seoul, Korea.
FAU - Kim, Sang Wun
AU  - Kim SW
AUID- ORCID: 0000-0002-8342-8701
AD  - Department of Obstetrics and Gynecology, Institute of Women's Medical Life
      Science, Yonsei University College of Medicine, Seoul, Korea.
FAU - Kim, Young Tae
AU  - Kim YT
AD  - Department of Obstetrics and Gynecology, Institute of Women's Medical Life
      Science, Yonsei University College of Medicine, Seoul, Korea.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20180906
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (CA-125 Antigen)
RN  - 0 (MUC16 protein, human)
RN  - 0 (Membrane Proteins)
RN  - 0 (Organoplatinum Compounds)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Antineoplastic Combined Chemotherapy Protocols/therapeutic use
MH  - Biomarkers, Tumor/blood
MH  - CA-125 Antigen/*blood
MH  - Cohort Studies
MH  - Cytoreduction Surgical Procedures
MH  - Disease-Free Survival
MH  - Drug Resistance, Neoplasm
MH  - Female
MH  - Humans
MH  - Kinetics
MH  - Membrane Proteins/*blood
MH  - Middle Aged
MH  - Models, Biological
MH  - Neoadjuvant Therapy/*methods
MH  - Organoplatinum Compounds/therapeutic use
MH  - Ovarian Neoplasms/*blood/*drug therapy/surgery
MH  - Prognosis
MH  - Retrospective Studies
MH  - Survival Analysis
PMC - PMC6126869
COIS- The authors have declared that no competing interests exist.
EDAT- 2018/09/07 06:00
MHDA- 2019/02/27 06:00
CRDT- 2018/09/07 06:00
PHST- 2018/03/08 00:00 [received]
PHST- 2018/08/20 00:00 [accepted]
PHST- 2018/09/07 06:00 [entrez]
PHST- 2018/09/07 06:00 [pubmed]
PHST- 2019/02/27 06:00 [medline]
AID - 10.1371/journal.pone.0203366 [doi]
AID - PONE-D-18-07247 [pii]
PST - epublish
SO  - PLoS One. 2018 Sep 6;13(9):e0203366. doi: 10.1371/journal.pone.0203366.
      eCollection 2018.